Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: Glycosaminoglycan storage is merely the instigator

Rheumatology

Volumn 50, Issue SUPPL. 5, 2011, Pages

  Clarke, Lorne A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; Arthropathy.; Dysostosis multiplex; Enzymereplacement therapy,Glycosaminoglycans; Inflammation; Lysosomal storage disease,Mucopolysaccharidosis; Proteoglycans; Signal transduction

Indexed keywords

ARTHROPATHY; ARTICLE; BONE DISEASE; CLINICAL FEATURE; CONNECTIVE TISSUE; DISEASE ASSOCIATION; ENZYME REPLACEMENT; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; MUCOPOLYSACCHARIDOSIS; PRIORITY JOURNAL; RHEUMATOLOGY; SKELETON MALFORMATION;

ANIMALS; BONE DISEASES; DISEASE MODELS, ANIMAL; GLYCOSAMINOGLYCANS; HUMANS; JOINT DISEASES; MUCOPOLYSACCHARIDOSES; SIGNAL TRANSDUCTION;

EID: 84855591153     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker395     Document Type: Article

References (44)

1. Neufeld ES, Muenzer J. The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B et al., eds. The Online Metabolic and Molecular Bases of Inherited Disease, Chapter 136. New York: McGraw-Hill, 2007.
2. McKusick VA, Kaplan D, Wise D et al. The genetic mucopolysaccharidoses. Medicine 1965; 44: 445-83.
3. Clarke L. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med 2008; 10: e1.
4. Woloszynek J, Roberts M, Coleman T et al. Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII. Biochem J 2004; 379: 461-9.
5. Garcia A, Pan J, Lamsa J et al. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 2007; 30: 924-34.
6. King B, Savas P, Fuller M et al. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. Mol Genet Metab 2006; 87: 107-12.
7. Metcalf J, Linders B, Wu S et al. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol Genet Metab 2010; 99: 396-407.
8. Metcalf J, Zhang Y, Hilton M et al. Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 2009; 97: 202-11.
9. Simonaro C, D'Angelo M, He X et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008; 172: 112-22.
10. Woloszynek J, Coleman T, Semenkovich C et al. Lysosomal dysfunction results in altered energy balance. J Biol Chem 2007; 282: 35765-71.
11. Ausseil J, Desmaris N, Bigou S et al. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 2008; 3: e2296.
12. Ma X, Tittiger M, Knutsen R et al. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol Genet Metab 2008; 94: 298-304.
13. Simonaro C, Ge Y, Eliyahu E et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 2010; 107: 222-7.
14. Walkley S. Pathogenic cascades in lysosomal disease-why so complex. J Inherit Metab Dis 2009; 32: 181-9.
15. Vitner E, Platt F, Futerman A. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Biol Chem 2010; 285: 20423-27.
16. Cimaz R, Coppa GV, Koné -Paut I et al. Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J 2009; 7: 18-25.
17. Cimaz R, Vijay S, Haase C et al. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin Exp Rheumatol 2006; 24: 196-202.
18. Pastores G, Meere P. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005; 17: 70-8.
19. Pastores G. Musculoskeletal complications encountered in the lysosomal storage disorders. Best Prac Res Clin Rheumatol 2008; 22: 937-47.
20. Al Kaissi A, Klaushofer K, Grill F. Progressive acetabular dysplasia in a boy with mucopolysaccharoidosis type IV A (Morquio syndrome): a case report. Cases J 2008; 1: 410-13.
21. Simonaro C, Haskins M, Schuchman E. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001; 81: 1319-28.
22. Simonaro C, D'Angelo M, Haskins M et al. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005; 57: 701-7.
23. De Franceschi L, Roseti L, Desando G et al. A molecular and histological characterization of cartilage from patients with Morquio syndrome. Osteoarthritis Cartilage 2007; 15: 1311-7.
24. Bank R, Groener J, van Gemund JJ et al. Deficiency in N-acetylgalactosamine-6-sulfate sulfatase results in collagen perturbations in cartilage of Morquio syndrome A patients. Mol Genet Metab 2009; 97: 196-201.
25. Russell C, Hendson G, Jevon G et al. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 1998; 53: 349-61.
26. Nuttall J, Brumfield L, Fazzalari N et al. Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcif Tissue Int 1999; 65: 47-52.
27. Wilson S, Hashamiyan S, Clarke. et al. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol 2009; 175: 2053-62.
28. Monroy M, Ross F, Teitelbaum S et al. Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease. Bone 2002; 30: 352-9.
29. Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A et al. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in Hurler syndrome. Pediat Res 2006; 59: 27-32.
30. Fesslová V, Corti P, Sersale G et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009; 19: 170-8.
31. Mohan U, Hay A, Cleary M et al. Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 2002; 91: 799-804.
32. Rigante D, Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology 2002; 98: 18-20.
33. Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000; 156: 925-38.
34. Ohmi K, Greenberg D, Rajavel K et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003; 100: 1902-7.
35. Walkley S, Vanier M. Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta 2009; 1793: 726-36.
36. Ryazantsev S, Yu W-H, Zhao H-Z et al. Lysosomal accumulation of SCMAS (subunit c of mitochondrial ATP synthase) in neurons of the mouse model of mucopolysaccharidosis III B. Mol Genet Metab 90: 393-401.
37. Ohmi K, Kudo L, Ryazantsev S et al. Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proc Natl Acad Sci USA 2009; 106: 8332-7.
38. Hemsley K, Hopwood J. Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010; 33: 363-71.
39. Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology 2011; 50(Suppl 5): v49-v59.
40. Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010; 47: 59-69.
41. Guffon N, Bertrand Y, Forest I et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009; 154: 733-7.
42. Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 485-98.
43. Gabrielli O, Clarke L, Bruni S et al. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010; 125: e183-7.
44. McGill J, Inwood A, Coman D et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 2010; 77: 492-8.